Literature DB >> 23200935

Disparate adjuvant properties among three formulations of "alum".

Derek W Cain1, Sergio E Sanders, Michael M Cunningham, Garnett Kelsoe.   

Abstract

Aluminum adjuvants, commonly referred to as "alum," are the most widespread immunostimulants in human vaccines. Although the mechanisms that promote humoral responses to alum-adsorbed antigens are still enigmatic, alum is thought to form antigen depots and induce inflammatory signals that, in turn, promote antibody production. It was recently noted that Imject(®) alum, a commercial aluminum-containing adjuvant commonly used in animal studies, is not the physicochemical equivalent of aluminum adjuvant present in human vaccines. This difference raises concerns about the use of Imject(®) alum in animal research as a model for approved aluminum adjuvants. Here, we compared the capacity of Imject(®) alum, Alhydrogel(®), and a traditional alum-antigen precipitate to induce humoral responses in mice to the hapten-carrier antigen, NP-CGG [(4-hydroxy-3-nitrophenyl)acetyl-chicken γ-globulin]. The magnitude of humoral responses elicited by Alhydrogel(®) and precipitated alum was significantly greater than that induced by Imject(®) alum. The strength of the humoral responses elicited by different alum formulations was correlated with the quantity of pro-inflammatory cytokines induced and the numbers of inflammatory cells at the site of immunization. Moreover, Imject(®) exhibited a severely reduced capacity to adsorb protein antigens compared to Alhydrogel(®) and precipitated alum. These findings reveal substantial differences in the immunostimulatory properties of distinct alum preparations, an important point of consideration for the evaluation of novel adjuvants, the assessment of new alum-based vaccines, and in mechanistic studies of adjuvanticity.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23200935      PMCID: PMC3541451          DOI: 10.1016/j.vaccine.2012.11.044

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  41 in total

1.  Predicting the adsorption of proteins by aluminium-containing adjuvants.

Authors:  S J Seeber; J L White; S L Hem
Journal:  Vaccine       Date:  1991-03       Impact factor: 3.641

2.  Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling.

Authors:  Amanda L Gavin; Kasper Hoebe; Bao Duong; Takayuki Ota; Christopher Martin; Bruce Beutler; David Nemazee
Journal:  Science       Date:  2006-12-22       Impact factor: 47.728

3.  Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms.

Authors:  Etsushi Kuroda; Ken J Ishii; Satoshi Uematsu; Keiichi Ohata; Cevayir Coban; Shizuo Akira; Kosuke Aritake; Yoshihiro Urade; Yasuo Morimoto
Journal:  Immunity       Date:  2011-04-14       Impact factor: 31.745

4.  Strain differences in the fine specificity of mouse anti-hapten antibodies.

Authors:  T Imanishi; O Mäkelä
Journal:  Eur J Immunol       Date:  1973-06       Impact factor: 5.532

Review 5.  Aluminium compounds as adjuvants for vaccines and toxoids in man: a review.

Authors:  M A Aprile; A C Wardlaw
Journal:  Can J Public Health       Date:  1966-08

Review 6.  A compendium of vaccine adjuvants and excipients.

Authors:  F R Vogel; M F Powell
Journal:  Pharm Biotechnol       Date:  1995

7.  Relationship between protein adsorptive capacity and the X-ray diffraction pattern of aluminium hydroxide adjuvants.

Authors:  H Masood; J L White; S L Hem
Journal:  Vaccine       Date:  1994-02       Impact factor: 3.641

8.  The immunobiology of aluminium adjuvants: how do they really work?

Authors:  Christopher Exley; Peter Siesjö; Håkan Eriksson
Journal:  Trends Immunol       Date:  2010-02-10       Impact factor: 16.687

9.  Inflammation triggers emergency granulopoiesis through a density-dependent feedback mechanism.

Authors:  Derek W Cain; Pilar B Snowden; Gregory D Sempowski; Garnett Kelsoe
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

10.  Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity.

Authors:  Amy S McKee; Michael W Munks; Megan K L MacLeod; Courtney J Fleenor; Nico Van Rooijen; John W Kappler; Philippa Marrack
Journal:  J Immunol       Date:  2009-09-04       Impact factor: 5.422

View more
  22 in total

1.  The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation.

Authors:  Jianjun Chen; Rebecca R Pompano; Felix W Santiago; Lea Maillat; Roger Sciammas; Tao Sun; Huifang Han; David J Topham; Anita S Chong; Joel H Collier
Journal:  Biomaterials       Date:  2013-08-13       Impact factor: 12.479

Review 2.  Adjuvants: Engineering Protective Immune Responses in Human and Veterinary Vaccines.

Authors:  Bassel Akache; Felicity C Stark; Gerard Agbayani; Tyler M Renner; Michael J McCluskie
Journal:  Methods Mol Biol       Date:  2022

3.  Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation.

Authors:  Gajalakshmi Dakshinamoorthy; Ramaswamy Kalyanasundaram
Journal:  Vaccine       Date:  2013-11-06       Impact factor: 3.641

4.  Complex Antigens Drive Permissive Clonal Selection in Germinal Centers.

Authors:  Masayuki Kuraoka; Aaron G Schmidt; Takuya Nojima; Feng Feng; Akiko Watanabe; Daisuke Kitamura; Stephen C Harrison; Thomas B Kepler; Garnett Kelsoe
Journal:  Immunity       Date:  2016-03-03       Impact factor: 31.745

5.  Immunization against Anaplasma phagocytophilum Adhesin Binding Domains Confers Protection against Infection in the Mouse Model.

Authors:  Waheeda A Naimi; Jacob J Gumpf; Ryan S Green; Jerilyn R Izac; Matthew P Zellner; Daniel H Conrad; Richard T Marconi; Rebecca K Martin; Jason A Carlyon
Journal:  Infect Immun       Date:  2020-09-18       Impact factor: 3.609

6.  The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm.

Authors:  Tirth Raj Ghimire
Journal:  Springerplus       Date:  2015-04-16

7.  IL-33 released by alum is responsible for early cytokine production and has adjuvant properties.

Authors:  William A Rose; Angela J Okragly; Chetan N Patel; Robert J Benschop
Journal:  Sci Rep       Date:  2015-08-14       Impact factor: 4.379

8.  Fluorescent nanodiamonds as a relevant tag for the assessment of alum adjuvant particle biodisposition.

Authors:  Housam Eidi; Marie-Odile David; Guillemette Crépeaux; Laetitia Henry; Vandana Joshi; Marie-Hélène Berger; Mohamed Sennour; Josette Cadusseau; Romain K Gherardi; Patrick A Curmi
Journal:  BMC Med       Date:  2015-06-17       Impact factor: 8.775

9.  Slow CCL2-dependent translocation of biopersistent particles from muscle to brain.

Authors:  Zakir Khan; Christophe Combadière; François-Jérôme Authier; Valérie Itier; François Lux; Christopher Exley; Meriem Mahrouf-Yorgov; Xavier Decrouy; Philippe Moretto; Olivier Tillement; Romain K Gherardi; Josette Cadusseau
Journal:  BMC Med       Date:  2013-04-04       Impact factor: 8.775

Review 10.  Heat shock proteins: stimulators of innate and acquired immunity.

Authors:  Camilo A Colaco; Christopher R Bailey; K Barry Walker; James Keeble
Journal:  Biomed Res Int       Date:  2013-05-25       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.